Gilead Signs an Exclusive License Agreement with Jounce for Cancer Immunotherapies

 Gilead Signs an Exclusive License Agreement with Jounce for Cancer Immunotherapies

Gilead Signs an Exclusive License Agreement with Jounce for Cancer Immunotherapies

Shots:

  • Jounce to receive $85M up front, $685B as clinical, regulatory, and commercial milestone payments, $35M equity investment at a premium in Jounce upon closing along with royalties on global sales of therapies including JTX-1811. The transaction is expected to be closed in H2’20
  • Jounce will lead the development of JTX-1811 through IND clearance, and thereafter, Gilead will be solely responsible to develop the therapy
  • JTX-1811 is a mAb, targeting CCR8 and selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells

Click here ­to­ read full press release/ article | Ref: Gilead | Image: Dragon Images

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post